Fig. 1

Single transaxial slice of a pre- and post-treatment study and dosimetry results (patient ID 42). a, b Late arterial phase CBCTs focusing on the left and right lobe; the contrast enhancement is used to segment the right and left LPT (green and blue area) and to segment the tumors (red and pink contours). c, d A fusion-view of ^99mTc-MAA SPECT/CT and ⁹⁰Y PET/MR images. The contours represent registered VOIs which are delineated on CBCTs masked by the total liver. e Baseline MR image, with red and pink arrow pointing to the tumors which have been delineated on CBCTs (a and b). f, g Dose-volume histograms of the tumor, non-tumoral liver parenchyma, and total LPT for left and right LPT from predictive(left lobe: tumor, non-tumoral tissue, and total LPT mean dose of 73, 26, and 28 Gy; right lobe: tumor, non-tumoral tissue, and total LPT mean dose of 160, 35, and 39 Gy) and post-treatment (left lobe: tumor, non-tumoral tissue, and total LPT mean dose of 106, 22, and 27 Gy; right lobe: tumor, non-tumoral tissue, and total LPT mean dose of 119, 35, and 38 Gy) dosimetry. h Dose-volume histogram of the tumor, non-tumoral liver parenchyma, and total liver when combining both LPTs from predictive dosimetry (tumor, non-tumoral tissue, and total LPT mean dose of 128, 32, and 36 Gy) and post-treatment dose measurement (tumor, non-tumoral tissue, and total liver mean dose of 115, 32, and 35 Gy)